Back to top
more

Immunocore (IMCR)

(Delayed Data from NSDQ)

$53.29 USD

53.29
788,907

-0.96 (-1.77%)

Updated May 17, 2024 04:00 PM ET

After-Market: $53.29 0.00 (0.00%) 4:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value B Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 34% (86 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sarepta's (SRPT) DMD Drug sBLA Gets FDA's Priority Tag, Stock Up

by Zacks Equity Research

Sarepta (SRPT) announces the FDA's acceptance of its efficacy supplement to the Elevidys BLA, seeking to expand the treatment label for its DMD drug. The stock gains 8%.

Zacks Industry Outlook Highlights Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology

by Zacks Equity Research

Sarepta, Exelixis, Immunocore, Editas and Puma Biotechnology have been highlighted in this Industry Outlook article.

Zoetis' (ZTS) Q4 Earnings Miss Expectations, Sales Beat

by Zacks Equity Research

Zoetis (ZTS) reports mixed fourth-quarter results, wherein earnings miss estimates while revenues beat the same.

Ekta Bagri headshot

5 Biotech Stocks to Consider for Your Portfolio in 2024

by Ekta Bagri

New drug approvals and pipeline progress are likely to help maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and solid pipeline progress position SRPT, EXEL, IMCR, EDIT and PBYI well amid volatility.

Immunovant (IMVT) Up 3% as Q3 Earnings Top, Pipeline in Focus

by Zacks Equity Research

Immunovant (IMVT) gains 3% on encouraging fiscal third-quarter 2024 results. Pipeline development is on track, with several data readouts scheduled from both batoclimab and IMVT-1402 programs.

Humacyte (HUMA) Up on HAV BLA Priority Tag for Vascular Trauma

by Zacks Equity Research

Humacyte (HUMA) gains 16% as the FDA accepts its BLA for the HAV bioengineered tissue to treat vascular trauma under Priority Review. A final decision is expected in August 2024.

REGENXBIO's (RGNX) Hunter Syndrome Study Meets Goal, Stock Up

by Zacks Equity Research

REGENXBIO (RGNX) gains 12% on positive top-line results from the phase I/II/III study of its investigational one-time gene therapy candidate, RGX-121, to treat pediatric patients with Hunter syndrome.

Immunome (IMNM) to Acquire Desmoid Tumor Candidate, Stock Up

by Zacks Equity Research

Immunome (IMNM) inks an asset purchase agreement with Ayala Pharmaceuticals to acquire the latter's investigational candidate, AL102, being developed for treating desmoid tumors. Stock rises.

Deciphera (DCPH) Q4 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Deciphera (DCPH) reports better-than-expected fourth-quarter 2023 results, wherein both earnings and revenues beat their respective estimates, driven by increased Qinlock sales.

Immunocore Holdings PLC Sponsored ADR (IMCR) Moves 6.9% Higher: Will This Strength Last?

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Best Momentum Stocks to Buy for January 10th

by Zacks Equity Research

IMCR, CPRX and AMPX made it to the Zacks Rank #1 (Strong Buy) momentum stocks list on January 10, 2024.

Should You Buy Immunocore Holdings PLC Sponsored ADR (IMCR) After Golden Cross?

by Zacks Equity Research

When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?

New Strong Buy Stocks for January 10th

by Zacks Equity Research

PCRFY, IMCR, CPRX, AMPX and ENS have been added to the Zacks Rank #1 (Strong Buy) List on January 10, 2024.

Immunocore Holdings PLC Sponsored ADR (IMCR) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

How Much Upside is Left in Immunocore Holdings PLC Sponsored ADR (IMCR)? Wall Street Analysts Think 30.32%

by Zacks Equity Research

The consensus price target hints at a 30.3% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Can Immunocore Holdings PLC Sponsored ADR (IMCR) Climb 75.55% to Reach the Level Wall Street Analysts Expect?

by Zacks Equity Research

The consensus price target hints at a 75.6% upside potential for Immunocore Holdings PLC Sponsored ADR (IMCR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Bears are Losing Control Over Immunocore Holdings PLC Sponsored ADR (IMCR), Here's Why It's a 'Buy' Now

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.

Wall Street Analysts See a 66.42% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?

by Zacks Equity Research

The mean of analysts' price targets for Immunocore Holdings PLC Sponsored ADR (IMCR) points to a 66.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 60.86% Upside in Immunocore Holdings PLC Sponsored ADR (IMCR): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 60.9% in Immunocore Holdings PLC Sponsored ADR (IMCR). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Why Earnings Season Could Be Great for Immunocore (IMCR)

by Zacks Equity Research

Immunocore (IMCR) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Immunocore Holdings PLC Sponsored ADR (IMCR) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

In the latest trading session, Immunocore Holdings PLC Sponsored ADR (IMCR) closed at $48.54, marking a -1.74% move from the previous day.

Immunocore Holdings PLC Sponsored ADR (IMCR) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $47.52, moving -0.71% from the previous trading session.

Immunocore Holdings PLC Sponsored ADR (IMCR) is Attracting Investor Attention: Here is What You Should Know

by Zacks Equity Research

Zacks.com users have recently been watching Immunocore Holdings PLC Sponsored ADR (IMCR) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

Immunocore Holdings PLC Sponsored ADR (IMCR) Stock Sinks As Market Gains: What You Should Know

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $46.71, moving -1.37% from the previous trading session.

Immunocore Holdings PLC Sponsored ADR (IMCR) Gains But Lags Market: What You Should Know

by Zacks Equity Research

Immunocore Holdings PLC Sponsored ADR (IMCR) closed the most recent trading day at $53.51, moving +1.61% from the previous trading session.